首页> 外文期刊>Journal of biochemical and molecular toxicology >Therapeutic potential of carfilzomib, an irreversible proteasome inhibitor, against acetaminophen‐induced hepatotoxicity in mice
【24h】

Therapeutic potential of carfilzomib, an irreversible proteasome inhibitor, against acetaminophen‐induced hepatotoxicity in mice

机译:Carfilzomib,一种不可逆的蛋白酶体抑制剂,对乙酰氨基酚诱导的小鼠肝毒性的治疗潜力

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Overdose of acetaminophen (APAP) is often associated with hepatotoxicity. Carfilzomib (CFZ) shows multiple pharmacological activities including anti‐inflammatory potential. Therefore, this study was undertaken to evaluate the possible therapeutic effects of CFZ against APAP‐induced hepatotoxicity. Hepatotoxicity was induced by administration of APAP (350?mg/kg, intraperitoneal). Mice were given CFZ (0.125, 0.25, or 0.5?mg/kg, intraperitoneal) 1.5?h after APAP administration. Animals were sacrificed on 6?h and blood and liver tissue samples were collected for analysis. In CFZ‐post‐treated group, there was significant and dose‐dependent decrease in serum alanine aminotransferase levels. The level of tumor necrosis factor‐α (TNF‐α), reactive oxygen species, and NO decreased, whereas glutathione increased significantly by CFZ post‐treatment. Upregulated mRNA expression of COX‐II and iNOS were significantly downregulated by CFZ post‐treatment. CFZ may exert its hepatoprotective action by alleviating inflammatory, oxidative, and nitrosative stress via inhibition of TNF‐α, COX‐II, and iNOS.
机译:摘要过量的乙酰氨基酚(APAP)通常与肝毒性有关。 Carfilzomib(CFZ)显示多种药理活动,包括抗炎潜力。因此,本研究旨在评估CFZ对APAP诱导的肝毒性的可能治疗效果。通过APAP(350×mg / kg,腹膜内)诱导肝毒性。在APAP给药后给予CFZ(0.125,0.25,或0.5×mg / kg,腹膜内)1.5·h。在6μl和血液和肝组织样品上处死动物进行分析。在CFZ后处理的组中,血清丙氨酸氨基转移酶水平显着和剂量依赖性降低。肿瘤坏死因子-α(TNF-α),反应性氧物质和没有降低的水平,而CFZ治疗后谷胱甘肽显着增加。 CFZ后处理显着下调COX-II和INOS的上调mRNA表达。 CFZ可以通过通过抑制TNF-α,COX-II和INOS来缓解炎症,氧化和氮化胁迫来发挥其肝保护作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号